This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC0Q1B5_M.jpg
Regeneron Pharma announced earnings per share of $8.36 on revenue of $2.29B. Analysts polled by Investing.com anticipated EPS of $6.97 on revenue of $2.08B.
Regeneron Pharma shares are up 56.37% from the beginning of the year, still down 11.66% from its 52 week high of $664.64 set on July 20. They are outperforming the S&P 500 which is up 6.58% from the start of the year.
Regeneron Pharma’s report follows an earnings beat by J&J on October 13, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Pfizer had beat expectations on October 27 with third quarter EPS of $0.72 on revenue of $12.13B, compared to forecast for EPS of $0.71 on revenue of $12.31B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
